1. Introduction

Over the past years, Alzheimer Europe has developed close working relations with a number of commercial companies which supported some of the activities of Alzheimer Europe. In order to provide greater transparency to the sponsoring agreements and to provide greater choice and flexibility to potential sponsors, Alzheimer Europe has developed the present document outlining the different sponsorship opportunities available to commercial companies.

Since Alzheimer Europe is committed to full transparency in all its dealings with commercial entities, all sponsorship will be duly acknowledged in the sponsor section of the Alzheimer Europe website (www.alzheimer-europe.org) and the financial section of the Annual Report of the organisation. Also, in line with the criteria for transparency developed by the European Medicines Agency, Alzheimer Europe will publish the full amounts received by commercial companies, as well as the percentage which those amounts constitute in relation to the total income of the organisation.

All sponsors will receive monthly updates on the various activities and projects of the organisation.

Alzheimer Europe welcomes contributions to the corporate affairs activities of the organisation, as well as to specific projects of Alzheimer Europe. While the following presents a list of the different sponsorship opportunities available to companies from Alzheimer Europe, the organisation will also happily discuss other projects and actions not mentioned in this document, but directly proposed by potential sponsors. For all its dealings with companies, Alzheimer Europe refers to its guidelines for working with commercial sponsors contained in an annex to this document.

2. Sponsorship levels for corporate affairs activities

In order to continue the tradition of some companies to support the entirety of the corporate affairs activities of Alzheimer Europe, Alzheimer Europe will provide a number of sponsorship packages to companies and the sponsors will receive a detailed list of benefits they will be able to count on.

For 2013, Alzheimer Europe would like to propose three levels of sponsorship.

Sponsorship level	Amount	Areas
Bronze sponsor	10,000€	Information Company Round-Tables
Silver sponsor	20,000€	Information Company Round-Tables Dementia-Monitor OR Alliance
Gold sponsor	40,000€	Information Company Round Tables Dementia-Monitor Dementia-Monitor AND Alliance

 According to the chosen level, Alzheimer Europe will provide a number of benefits to the sponsor. These benefits are outlined in the table below.

Benefits	Gold	Silver	Bronze
General benefits
Acknowledgement in Sponsor section of AE website	√	√	√
Acknowledgement in AE Annual Report	√	√	√
Invitation to Company Round Table	√	√	√
Monthly Update on AE activities	√	√	√
Dementia in Europe Magazine
Advertisement in Dementia in Europe Magazine	3 x half page	2 x half page	1 x half page
Free copies of the magazine	50	20	10
Dementia-Monitor
Invitation to working group meetings	√	OR
Invitation to launch event in European Parliament and acknowledgement on Dementia-Monitor documents	√	OR
European Alzheimer’s Alliance
Acknowledgement of support on Alliance documents	√	OR
Invited representatives to Alliance meetings	1	OR

3. Sponsorship opportunities

3.1. Company Round Tables

In conjunction with its Board meetings, Alzheimer Europe will organise meetings with interested companies in order to discuss common issues with regard to the research and regulatory environment.

Alzheimer Europe will present its plans and activities at these meetings. In addition, the organisation will liaise with the participating companies to identify issues of common interest and will invite company representatives to make presentations on selected topics.

Alzheimer Europe hopes that these joint meeting will serve as a frank exchange of information and views and lead to a better understanding of the positions of Alzheimer associations and industry.

At these meetings, time can be allocated for those companies interested in sharing their research activities and discussing issues such as design of clinical trial protocols or patient recruitment with representatives of the Alzheimer Europe Board. If necessary, this section of the meeting will be closed to invited representatives only and AE participants may be required to sign confidentiality agreements to cover the discussions on issues not in the public domain.

3.2. Dementia in Europe Magazine

Alzheimer Europe will continue publishing its special magazine entitled “Dementia in Europe” with a clear focus on policy developments in different European countries. This magazine will also update readers on the state of signatures of the Paris Declaration and will highlight any initiatives on a national or European level that are in line with the political priorities of the declaration.

The magazine will be published three times in 2013 and will be distributed free of charge to Members of the European Parliament and the European Commission, as well as through the member organisations of Alzheimer Europe to national policy makers. Furthermore, the magazine will be distributed to other European stakeholders who currently receive the e-mail newsletter of the organisation. Special attention will also be paid to disseminating the AE magazine to the media contacts of the organisation.

The printed magazine will not be called upon to replace the e-mail newsletter of the organisation which will continue to focus on the activities of Alzheimer Europe and on scientific breakthroughs in the dementia field. The printed magazine will not cover these aspects, but will be focused solely on policy initiatives.

It is envisaged to also include interviews with European and national policy makers in the newsletter and to give the possibility to researchers interested in the public health aspects of dementia to publish articles in the Alzheimer Europe newsletter.

3.3. Dementia Monitor

When adopting the Paris Declaration, Alzheimer Europe and its national member organisations called on national governments to make dementia a national priority. The degree to which governments have responded to this call varies greatly.

As a next step, AE will collaborate with its member organisations and its corporate sponsors on identifying common indicators to measure and compare national dementia policies. AE will in particular aim at identifying statistical information which would allow a benchmarking of national policies (i.e. numbers of people with dementia diagnosed and treated, number of neurologists, old age psychiatrists or other healthcare professionals, treatments reimbursed, nursing home places, day care centres, MRI scanners etc.)

The findings will be presented at a lunch debate in the European Parliament in December 2013.

3.4. European Alzheimer’s Alliance

The European Alzheimer’s Alliance set up by Alzheimer Europe brings together 65 Members of the European Parliament from different political parties and countries. The Alliance will meet at least twice in 2013 to discuss the state of development of the different EU initiatives on dementia and of national dementia strategies.

Throughout the year, Members of the European Parliament will be regularly updated on this through direct contacts via the Public Affairs Officer of Alzheimer Europe, as well as through regular e-mail updates and the magazine.

4. Conference Sponsorship

For its 2013 Annual Conference in St. Julian’s, Malta (10-12 October 2013), Alzheimer Europe chose the motto “Living well in a dementia friendly society” which the association will organise with the support of the European Commission.

The following sponsorship packages will be available. Silver sponsors of Alzheimer Europe will receive a discount of 25% on these packages and platinum and gold sponsors a discount of 50%.

Sponsorship Opportunities
Bronze conference sponsor (€5,000)	Your logo on all printed documents (programme, participants pack, book of abstracts) Your logo on the website (www.alzheimer-europe.org/conferences) Your logo on screen in meeting rooms at beginning of sessions One complimentary registration to the AE Conference
Silver conference sponsor (€10,000)	As bronze sponsorship, including Half page non-promotional advert in conference programme Company stand in exhibition area of conference Two complimentary registrations to the AE Conference
Gold conference sponsor Limited to a maximum of four (€20,000)	As silver sponsorship, including Full page non-promotional advert in conference programme Satellite symposium (breakfast symposium or evening symposium outside conference hours) Four complimentary registrations to the AE Conference

 

5. Annex: AE Rules and regulations - Chapter X. Co-operation with the pharmaceutical industry and other sponsors

Article 33 – Sponsorship guidelines

The following guidelines are a first attempt to harmonise the relationship between European Alzheimer associations and the pharmaceutical industry.

1. AE welcomes the development of new anti-dementia drugs and the investment of the pharmaceutical industry in this field and will seek to establish close contacts with the relevant companies. It hopes to be kept informed of new developments in this sector.
2. In all dealings with the pharmaceutical industry, AE and its national organisations shall remain impartial and shall not endorse a particular manufacturer or a particular product.
3.  Therefore AE and its national associations shall not enter into any agreement, which could threaten their non-profit status.
4. Information about members, donors or other confidential information about AE and its national associations shall remain the exclusive property of these and shall not be made available to any third party.
5. Information on drugs or clinical trials shall not be presented by AE or its national member associations unless it has been written by persons appointed by the organisations to do so.
6. AE and its national member associations are free to accept donations from pharmaceutical companies and other third parties. They will acknowledge such donations in the same way they acknowledge other donations by private persons.
7. When accepting sponsorship by pharmaceutical companies or other third parties, AE and its national member associations may acknowledge this sponsorship by appropriate means. Under no circumstances will this acknowledgement include an advertisement for a product.
8. Sponsorship does not entitle pharmaceutical companies and other third parties to determine the content of any publication or other information material produced by AE and its national members, nor does it entitle them to determine the programme or speakers at a conference or symposium organised by AE and its national members. At all times, AE and its members should have complete editorial and managerial control.
9. AE and its national member associations can lend their support for the development of information material or awareness campaigns by the pharmaceutical companies. Under no circumstances shall AE or its members give their support or logo for a campaign designed to advertise a product.
10. At all times, AE and its members will make sure that corporate support for their programs and materials cannot be interpreted as their endorsement of a business, company or product and they will take all necessary steps to avoid such appearance.
11. These guidelines constitute a minimal consensus between AE and its member organisations. They are binding on AE whereas the member organisations of AE have the right to adopt other Regulations not in conflict with the principles declared above for their dealings with the pharmaceutical industry and other third parties.
12. AE is bound by those guidelines and will not lend its support to events or publications of its member organisations or other interested parties that do not comply with them. The patronage or sponsorship of AE is therefore conditional on the acceptance of these guidelines by the applicant for sponsorship or patronage. AE will withdraw its support if in the course of a project or event, these guidelines are no longer respected.